Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04839744
Other study ID # SYSA1803-CSP-005
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 18, 2021
Est. completion date July 2, 2021

Study information

Verified date December 2021
Source CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to evaluate the comparability of TG103 injection subject to changes in the manufacturing process in Chinese healthy male subjects.


Description:

This is a randomized, open-label, parallel-group, comparative study to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, safety, and immunogenicity of TG103 injection produced by two different manufacturing processes in Chinese healthy male subjects. Approximately 24 eligible subjects will be randomized in a 1:1 ratio to receive a single dose of TG103 produced by the modified manufacturing process or TG103 produced by the original manufacturing process via subcutaneous (SC) injection.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date July 2, 2021
Est. primary completion date June 15, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - 1. Male subjects between 18 and 45 years of age, inclusive; - 2. The subject is in good health as determined by medical history, physical examination and clinical laboratory parameters, such as vital signs, 12-lead ECG, imaging examinations (such as thyroid color Doppler ultrasound, abdominal color Doppler ultrasound, chest X-ray); - 3. Weight = 50kg, body mass index (BMI) between 19-26 kg / m2 (inclusive) [BMI = weight (kg) / height 2 (m2)]; - 4. The subject has a blood glucose between 3.9-6.1 mmol / L (exclusive) and the HbA1c < 6.5%; - 5. From the date of signing an informed consent to at least 3 months after the administration, the subject must use reliable contraceptive methods to prevent pregnancy; - 6. The subjects fully understand the content of the trial and the possible adverse reactions, have the ability to communicate with the researchers normally, willing and able to comply with all requirements defined in the protocol; - 7. Voluntarily to participate in the study and sign the informed consent form. Exclusion Criteria: - 1. Subjects who have a history of certain allergic conditions (such as asthma, urticaria), or have a history of allergy to two or more drugs or food, or may be allergic to the test drug and the related compounds; - 2. Have a history of serious diseases, such as neurological, hepatic, renal, cardiovascular, haematological, pulmonary diseases, or other significant diseases capable of significantly altering the absorption, metabolism, or elimination of the study drug, of constituting a risk when taking the study drug; or of interfering with the interpretation of data; - 3. Have undergone major surgery within 3 months before screening or have severe infection within 4 weeks before screening; - 4. With thyroid dysfunction requiring drug treatment, or not reaching clinical stability after treatment, or with other endocrine diseases that may affect blood glucose metabolism; - 5. Have a history of or current pancreatitis (history of chronic or acute pancreatitis); - 6. Have a history of or current cholecystitis; - 7. With clinically significant abnormal gastric emptying (such as gastric outlet obstruction) and severe chronic gastrointestinal diseases (such as active ulcer within 6 months); - 8. Have a history (or family history) of medullary thyroid cancer (MTC), type 2 multiple endocrine neoplasia syndrome or other hereditary diseases that are thought to induce MTC; - 9. Have a history of malignant tumour, mental illness, depression, anxiety and epilepsy; - 10. Have a history of drug dependence in the past one year or have a positive urine drug screen before administration; - 11. Vaccinated within 28 days before screening or planned to be vaccinated within 1 week after receiving the study drug; - 12. Have a positive test result of hepatitis B surface antigen, hepatitis C antibody, anti-human immunodeficiency virus antibody or anti-Treponema pallidum specific antibody; - 13. Blood loss greater than 400 ml due to blood donation or other reasons within 3 months before screening; - 14. Have used Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 receptor agonists or any other incretin analogues three months before the planned study drug , or other drugs that are thought to affect the trial in the opinion of the researchers; - 15. Within 3 months before administration, subjects used drugs that may cause changes in blood glucose level; - 16. Have used any prescription drug, Chinese herbal medicine or over-the-counter drug within 15 days before screening that are capable of affecting the PK, PD and safety outcomes; - 17. Average alcohol intake is more than 21 units of alcohol (male) per week (1 unit ˜ 360mL beer, or 45mL spirits with 40% alcohol content, or 150mL wine) within the 3 months prior to screening, or a positive ethanol breath test at screening; - 18. Regularly consumption of caffeine is more than 600 mg per day within the 3 months prior to screening (one cup of coffee contains about 100 mg of caffeine, one cup of tea contains about 30 mg of caffeine, and one can of coke contains about 20 mg of caffeine), or those who used caffeinated products within 48 hours before administration; - 19. Smoking more than 5 cigarettes per day within 3 months prior to screening; - 20. According to the judgment of the researcher, the subjects have special dietary requirements; - 21. With dermatitis or abnormal skin conditions at or around the site of administration; - 22. Have participated in another clinical trial involving an investigational product within 3 months prior to the planned administration of the study drug; or the last dose of the previous investigational product has been given in less than 3 months before the screening; or those who would try to participate in other clinical trials during the study period; - 23. Not suitable for this study in the researcher's opinion, such as subjects with poor compliance (long-term business trip, planned relocation, etc.).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TG103 produced by the modified manufacturing process
Drug: TG103 (a modified manufacturing process), 15mg, SC
TG103 produced by the original manufacturing process
Drug: TG103 (the original manufacturing process), 15mg, SC

Locations

Country Name City State
China The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak Plasma Concentration (Cmax) Day1-5, 7,9,10, 15, and 28
Primary Area under the plasma concentration versus time curve (AUC) Day1-5, 7,9,10, 15, and 28
Secondary Change from baseline in Fasting blood glucose(FPG) Pharmacodynamic (PD) parameters after administration of of TG103 Day1-5, and 7
Secondary Change from baseline in 2-hour postprandial blood glucose(2hPG) Pharmacodynamic (PD) parameters after administration of of TG103 Day1-5, and 7
Secondary Number of participants with treatment-emergent adverse events Pharmacodynamic (PD) parameters after administration of of TG103 Up to 28 days
Secondary Concentration of Antidrug antibodies(ADA) ADA after administration of of TG103 Day1, 15, and 28
See also
  Status Clinical Trial Phase
Completed NCT05621447 - A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects Phase 1
Completed NCT02901366 - Mass Balance Study of FYU-981 Phase 2
Not yet recruiting NCT01928563 - Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine Phase 1
Completed NCT05559554 - A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects Phase 1
Completed NCT04512872 - A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects Phase 1
Active, not recruiting NCT06111196 - Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects Phase 1
Completed NCT03317652 - Effect of Sodium Nitroprusside on Cerebral Blood Flow N/A
Completed NCT04655872 - Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects Phase 1
Active, not recruiting NCT02609711 - Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects Phase 1
Withdrawn NCT02560363 - A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects Phase 1
Completed NCT01261260 - Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers Phase 1
Completed NCT05072028 - Mass Balance and Biotransformation Study of [14C]DBPR108 in Human Phase 1
Completed NCT05446233 - ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects Phase 1
Completed NCT05275010 - A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System Phase 1
Completed NCT05792917 - Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers Phase 1
Completed NCT03576651 - A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers Phase 1
Completed NCT04825431 - Mass Balance Study of [14C] TAS-205 in Healthy Volunteers Phase 1
Completed NCT01819779 - Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60) Phase 1
Completed NCT05126784 - AVT03 With Prolia in Healthy Male Subjects Phase 1
Completed NCT04850638 - Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control) Phase 1